Table 2 The risk of malignancy in current study and comparison with a few previous publications
Author | Specimen type | Year | Total cases | Risk of malignancy(ROM) | ||||
|---|---|---|---|---|---|---|---|---|
ND | NFM | AUS | SFM | MAL | ||||
Sahar J. F et al [15] | PF + AF + PeriF | 2019 | 34,941 | 17.4% | 20.7% | 65.9% | 81.8% | 98.9% |
Ediel V et al [14] | PF | 2019 | 519 | 50% | 44% | 50% | 83.3% | 96.2% |
Cláudia L et al [10] | PF/AF/ PeriF | 2020 | 1496/763/64 | 57.1%/100%/- | 23.9%/26.3%/0% | 50%/62.5%/0% | 76.2%/91.7%/- | 100%/100%/100% |
Yi X et al [11] | PF | 2021 | 2454 | 26.7% | 12%, | 62.3% | 77.8% | 100% |
Shilpy J et al [12] | PF | 2021 | 939 | 87.5% | 51.6% | 88.2% | 87.5% | 100% |
Daniel P et al [13] | PF | 2021 | 350 | 40% | 20.16% | 42.86% | 78.57% | 100% |
Tieying H et al [6] | PF + AF + PeriF | 2021 | 2405 | - | - | 39% | 64% | - |
Current study | PF + AF + PeriF | 2021 | 3588 | 38.5%(5/13) | 28.6%(304/1064) | 52.1%(50/96) | 99.4%(673/677) | 100%(1738/1738) |
PF | 2326 | 40%(4/10) | 29.8%(206/691) | 49.3%(36/73) | 99.3%(439/442) | 100%(1110/1110) | ||
AF | 1145 | 0%(0/2) | 27.5%(90/327) | 60.9%(14/23) | 99.5%(221/222) | 100%(571/571) | ||
PeriF | 117 | 100%(1/1) | 17.4%(8/46) | 0%(0/0) | 100%(13/13) | 100%(57/57) | ||